切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2016, Vol. 10 ›› Issue (06) : 406 -409. doi: 10.3877/cma.j.issn.1674-0793.2016.06.005

所属专题: 文献

论著

干细胞标记物Lgr5在胃癌组织中的表达及临床意义
黄江龙1,(), 魏波1, 郑宗珩1, 刘健培1, 陈图锋1, 黄勇1, 方佳峰1   
  1. 1. 510630 广州,中山大学附属第三医院胃肠外科
  • 收稿日期:2016-03-05 出版日期:2016-12-01
  • 通信作者: 黄江龙
  • 基金资助:
    广东省科技计划项产学研合作项目(2014B090901066); 广东省自然科学基金-博士启动项目(2015A030310052); 广州市产学研协同创新重大专项项目(2060404); 广东省医学科研基金资助项目(B2013127)

Expression and clinical significance of stem cell marker Lgr5 protein in human gastric carcinoma

Jianglong Huang1,(), Bo Wei1, Zongheng Zheng1, Jianpei Liu1, Tufeng Chen1, Yong Huang1, Jiafeng Fang1   

  1. 1. Department of Gastrointestinal Surgery, the Third Affiliated Hospital of Sun Yat-sen University, GuangZhou 510630, China
  • Received:2016-03-05 Published:2016-12-01
  • Corresponding author: Jianglong Huang
  • About author:
    Corresponding author: Huang Jianglong, Email:
引用本文:

黄江龙, 魏波, 郑宗珩, 刘健培, 陈图锋, 黄勇, 方佳峰. 干细胞标记物Lgr5在胃癌组织中的表达及临床意义[J]. 中华普通外科学文献(电子版), 2016, 10(06): 406-409.

Jianglong Huang, Bo Wei, Zongheng Zheng, Jianpei Liu, Tufeng Chen, Yong Huang, Jiafeng Fang. Expression and clinical significance of stem cell marker Lgr5 protein in human gastric carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(06): 406-409.

目的

分析干细胞标记物Lgr5(富含亮氨酸重复单位的G蛋白偶联受体5)蛋白在人胃癌组织中的异常表达,并探讨在胃癌肿瘤的发生发展等过程中发挥的作用。

方法

选取2012年1月至2015年6月接受胃癌手术治疗的70例患者,采用免疫组化法分别检测70例胃正常组织、癌旁组织、胃腺癌标本中Lgr5的蛋白表达,并统计学分析其与临床病理指标、患者生存预后的关系。

结果

70例胃癌组织中的Lgr5蛋白阳性表达率(50/70,71.4%)明显高于癌旁组织(35/70,50.0%)、正常组织(21/70,30.0%),差异有统计学意义(χ2=6.738、24.034,P=0.009、0.000);Lgr5蛋白的表达与胃癌患者的性别、年龄及分化程度无明显相关性,与淋巴结节转移、TNM分期密切相关(均P<0.05)。随访胃癌患者66例,其中Lgr5阳性组47例,Lgr5阴性组19例,生存分析两组术后3年生存率差异有统计学意义(χ2=3.929,P=0.047)。

结论

Lgr5蛋白在胃癌发生过程中可能发挥一定作用,它与胃癌的侵袭、转移和预后明显相关,Lgr5的表达检测可作为判断胃癌患者预后的一种手段。

Objective

To investigate the expression and its significance of Lgr5 protein in gastric cancer.

Methods

Lgr5 expression was detected by immunohistochemistry in normal tissues, paracancerous tissues and gastric cancer tissues of 70 patients with gastric cancer treated from January 2012 to June 2015. Clinicopathological information and prognosis data of these 70 patients were analyzed to figure out the role of Lgr5 in gastric cancer.

Results

The expression rate of Lgr5 in tumor tissues (50/70, 71.4%) was significant higher than that in both normal tissues (21/70, 30.0%, χ2=24.034, P=0.000) and paracancerous tissues (35/70, 50.0%, χ2=6.738, P=0.009). Lgr5 expression was significantly correlated with TNM stage and lymph node metastasis. There was no correlation between expression of Lgr5 with age, differentiation, and clinical characteristics in gastric cancer. Kaplan-Meier analysis showed significant difference in 3-year survival rates between groups with and without Lgr5 expression (χ2=3.929, P=0.047).

Conclusions

Expression of Lgr5 in gastric cancer indicates that stem cells may be involved in the pathogenesis of gastric cancer and Lgr5 may play an important role in the development and progression of gastric cancer. Lgr5 expression might be a useful marker of poor prognosis in gastric cancer.

表1 Lgr5蛋白在胃正常组织、癌旁组织、胃腺癌标本中的表达(例)
图1 免疫组织化学方法检测Lgr5在正常胃组织、癌旁组织和胃腺癌组织中的表达(SP法×200)
表2 Lgr5蛋白的表达与胃癌临床病理特征之间的关系(例)
图2 Lgr5蛋白阳性表达及阴性表达的胃癌患者生存曲线
1
Siegel R,Naishadham D,Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
2
Ong BA,Vega KJ,Houchen CW. Intestinal stem cells and the colorectal cancer microenvironment[J]. World J Gastroenterol, 2014, 20(8): 1898-1909.
3
Ribatti D. Cancer stem cells and tumor angiogenesis[J]. Cancer Lett, 2012, 321(1): 13-17.
4
Oliveras-Ferraros C,Vazquez-Martin A,Cuyàs E, et al. Ac-quired resistance to metformin in breast cancer cells triggers tran-scriptome reprogramming toward a degradome-related metastatic stem-like profile[J]. Cell Cycle, 2014, 13(7): 1132-1144.
5
Paldino E,Tesori V,Casalbore P, et al. Tumor initiating cells and chemoresistance: which is the best strategy to target colon cancer stem cells?[J]. Biomed Res Int, 2014, 2014: 859871.
6
Crowder SW,Balikov DA,Hwang YS, et al. Cancer stem cells un-der hypoxia as a chemoresistance factor in breast and brain[J]. Curr Pathobiol Rep, 2014, 2(1): 33-40.
7
Vermeulen L,Morrissey E,van der Heijden M, et al. Defining stem cell dynamics in models of intestinal tumor initiation[J]. Sci-ence, 2013, 342(6161): 995-998.
8
Schmitz V,Barajas M,Wang L, et al. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma[J]. Hepatology, 2001, 34(1): 72-81.
9
Barker N,van Es JH,Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5[J]. Nature, 2007, 449(7165):1003-1007.
10
Barker N,Ridgway RA,van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer[J]. Nature, 2009, 457(7229): 608-611.
11
Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration[J]. Nat Rev Mol Cell Biol, 2014, 15(1): 19-33.
12
Tanese K,Fukuma M,Yamada T, et al. G-protein-coupled recep-tor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation[J]. Am J Pathol, 2008, 173(3): 835-843.
13
Becker L,Huang Q,Mashimo H. Immunostaining of Lgr5, an in-testinal stem cell marker, in normal and premalignant human gastrointestinal tissue[J]. ScientificWorldJournal, 2008, 8: 1168-1176.
14
Hartgrink HH,Jansen EP,van Grieken NC, et al. Gastric cancer[J]. Lancet, 2009, 374(9688): 477-490.
15
Yamanoi K,Fukuma M,Uchida H, et al. Overexpression of leu-cine-rich repeat-containing G protein-coupled receptor 5 in gas-tric cancer[J]. Pathol Int, 2013, 63(1): 13-19.
16
Bu Z,Zheng Z,Zhang L, et al. LGR5 is a promising biomarker for patients with stage Ⅰand Ⅱ gastric cancer[J]. Chin J Cancer Res, 2013, 25(1): 79-89.
17
刘元华,樊祥山,恽艳.应用组织芯片技术检测胃癌组织中Lgr5和CD44的表达[J].中国肿瘤外科杂志, 2015, 7(6): 341-345.
[1] 庄蕙嘉, 岳志成, 钟坤岑, 朱慧莉. 乳腺癌患者生育力保存的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(04): 238-242.
[2] 卫杨文祥, 黄浩然, 刘予豪, 陈镇秋, 王海彬, 周驰. 股骨头坏死细胞治疗的前景和挑战[J]. 中华关节外科杂志(电子版), 2023, 17(05): 694-700.
[3] 韩李念, 王君. 放射性皮肤损伤治疗的研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 533-537.
[4] 李越洲, 张孔玺, 李小红, 商中华. 基于生物信息学分析胃癌中PUM的预后意义[J]. 中华普通外科学文献(电子版), 2023, 17(06): 426-432.
[5] 张俊, 罗再, 段茗玉, 裘正军, 黄陈. 胃癌预后预测模型的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 456-461.
[6] 闫笑生, 郑智, 翟育豪, 张海翘, 王鈢, 刘小野, 尹杰, 张军. Borrmann Ⅳ型胃癌临床诊断、病理特征及预后分析[J]. 中华普通外科学文献(电子版), 2023, 17(05): 346-351.
[7] 王龙彪, 刘洪, 董天雄. 中心体扩增细胞占比和C反应蛋白-白蛋白比值对胃癌根治术治疗预后的预测价值[J]. 中华普通外科学文献(电子版), 2023, 17(05): 352-356.
[8] 莫波, 王佩, 王恒, 何志军, 梁俊, 郝志楠. 腹腔镜胃癌根治术与改良胃癌根治术治疗早期胃癌的疗效[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 644-647.
[9] 陈大敏, 曹晓刚, 曹能琦. 肥胖对胃癌患者手术治疗效果的影响研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 651-653.
[10] 张彬, 贾贵清, 吴东松, 曹绿洲, 张焰凌, 黄灏, 赵高平. 早期胃癌保功能手术治疗13例病例分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 575-579.
[11] 王鸿彬, 何晓, 吴菁宙. 腹腔镜近端胃切除术中背驮式间置空肠单通道重建术在AEG手术的安全性及抗反流效果研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 526-529.
[12] 宋钰, 赵阳, 王惠君, 廖新华. 术前BMI与可切除胃癌患者术后远期生存的关系[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 530-533.
[13] 高静, 严学倩, 及月茹, 郝淼旺, 刘苍春. 胃癌患者以慢性贫血为首发表现的高危因素Logistic分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 534-537.
[14] 孔欣, 宋宝全, 刘吟, 张剑, 仇惠英, 吴德沛. 异基因造血干细胞移植并发难治性呃逆一例[J]. 中华移植杂志(电子版), 2023, 17(04): 253-255.
[15] 梁宇同, 丁旭, 马国慧, 黄艳红. 间充质干细胞在宫腔粘连治疗中的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 596-599.
阅读次数
全文


摘要